Sexual differentiation of the malaria parasite is a pre-requisite for transmission from humans to the mosquito vector and has emerged as a target for intervention in eradication efforts. In this issue of Cell, a study from Marti, Clardy, and colleagues (Brancucci et al., 2017 ) describes a host-derived lipid lysophosphatidylcholine (LysoPC) that regulates sexual commitment.
Malaria continues to ravage much of the developing world with over one hundred countries affected and half the world's population living in areas at risk of malaria transmission. Malaria is caused by singlecelled eukaryotic parasites of the genus Plasmodium that demonstrate a complex life cycle in humans and female mosquito hosts. The life cycle initiates with the bite of a mosquito, which delivers Plasmodium sporozoites that go on to establish a liverstage infection. A small number of infected hepatocytes will eventually release thousands of merozoites, which invade red blood cells and initiate the cyclic intraerythrocytic stage ( Figure 1 ). The clinical symptoms of malaria (including fever, aches, and malaise) result from waves of asexual blood-stage replication, which, in severe cases, progress to anemia, acidosis, multiple organ failure, and ultimately death if left untreated. Onward transmission of the parasite to the mosquito vector requires differentiation into male and female sexual forms during blood-stage development ( Figure 1 ).
Curiously, among P. falciparum strainsand even clones-the rate of gametocyte conversion varies but is generally low, with less than 10% of parasites producing gametocytes in each 48-hr intraerythrocytic cycle (Kafsack et al., 2014) . A mechanistic understanding of this cellular transformation process has been lacking and is therefore the subject of intense investigation. In the elegant study led by Matthias Marti, Jon Clardy, and colleagues in this issue of Cell, the authors provide an important initial step toward understanding how malaria parasites may be sensing and responding to changing host conditions to initiate sexual differentiation (Brancucci et al., 2017) .
Numerous reports have suggested that factors that ''stress'' asexually replicating parasites in the blood-stage-such as exposure to drugs and growth in spent medium-can induce gametocytogenesis. In terms of the key molecular drivers of gametocytogenesis, little is known, but we do know that a transcription factor called AP2-G is absolutely required for malaria parasites to commit to sexual development (Kafsack et al., 2014; Sinha et al., 2014) . In the majority of asexually replicating parasites, the ap2-g locus is silenced by histone H3 lysine9 trimethylation (H3K9me3) and heterochromatin protein 1 (HP1) (Josling and Lliná s, 2015) . Although the details regarding upstream activation of the ap2-g gene are still under investigation, recent studies have demonstrated that depletion of HP1, as well as histone deacetylase 2 (HDA2), can unsilence the ap2-g locus, enabling sexual differentiation to proceed.
Brancucci et al. identify lysophosphatidylcholine (LysoPC) as a critical molecule found in human serum that significantly impacts gametocyte formation. Building on a previous study in which they found that parasites grown in the presence of spent serum had increased gametocyte production (Brancucci et al., 2015) , they use fractionation coupled with mass spectrometry to identify serum components that lead to decreased gametocyte formation. LysoPC is exclusively present in fractions that block commitment to gametocytogenesis. The authors go on to further demonstrate that there is a critical window between 34 and 38 hr post red blood cell invasion (hpi) where LysoPC depletion leads to irreversible commitment to sexual differentiation.
During the intraerythrocytic stage of development, each malaria parasite develops into a schizont that produces 16 to 32 new merozoites. Most of these parasites will reinvade new red blood cells and develop asexually, while merozoites from sexually committed (34-38 hpi) schizonts reinvade and develop to become either all male or all female mature gametocytes ( Figure 1 ) (Silvestrini et al., 2000; Smith et al., 2000) . Schizogony requires that parasites produce a large number of phospholipids. These include phosphatidylcholine-the most abundant membrane phospholipid in P. falciparum-and phosphatidylethanolamine, which are made through the consumption of serine, choline, and ethanolamine from the host serum. Brancucci et al. use metabolic tracing experiments to demonstrate that exogenous LysoPC from the serum can cross several membranes to reach the parasite. Once inside the parasite, it is metabolized into choline and converted via the Kennedy pathway into phosphatidylcholine, an essential component of membranes. The importance of the Kennedy pathway is further exemplified by their demonstration that exogenously supplied choline alone (albeit not at non-physiologically high levels) could also block gametocyte conversion.
One of the most intriguing aspects of the current study comes out of the dissection of gene expression changes triggered by differential availability of LysoPC ( Figure 1 ). When LysoPC is depleted, the AP2-G transcription factor is activated along with upregulation of phosphoethanolamine methyltransferase (PMT), S-adenosylmethionine (SAM) synthetase, and other factors that intersect with this metabolic pathway. This cellular response suggests that LysoPC depletion likely results in increased production of SAM as a means to metabolically adjust to maintain an active Kennedy pathway. The upregulation of PMT is consistent with previous studies demonstrating that PMT is downregulated at both the transcriptional and protein level in the presence of choline and plays a critical role in the formation of mature gametocytes (Bobenchik et al., 2013; Pessi et al., 2004) . In addition to the genes involved in metabolism, transcription of a number of genes involved in cell cycle regulation and differentiation-such as the sirtuin sir2a, histone deacetylase 1 (hda1), lysine-histone demethylase 1 (lsd1), and the gametocyte development protein 1 (gdv1)-are also impacted by LysoPC metabolism.
Although metabolic depletion of LysoPC is clearly critical to the process of gametocyte formation, we are still left pondering the mechanistic aspects of how the levels of LysoPC trigger a cascade of events that result in ap2-g activation and downstream sexual differentiation. One tantalizing possibility is that under serum-rich conditions, phospholipid production relies on exogenous sources of choline, with minimal reliance on SAM-dependent enzymes. In serumrich conditions, cellular pools of SAM would be more readily available in the nucleus, where it serves as a methyl donor for a number of histone methyltransferases, which in turn repress expression via deposition of H3K9me3. In the converse situation, LysoPC-or serum-depleted conditions may lead to increased utilization of SAM by PMT and other cytoplasmic enzymes, switching methyltransferase activity out of the nucleus. Consequently, this may lead to a decreased availability of SAM in the nucleus and downstream loss of repressive H3K9me3 (Figure 1 ). This would suggest that the key link between depletion of LysoPC, transcriptional activation of AP2-G, and enhanced gametocyte production is likely to be modulation of SAM levels, and consequently, histone methylation.
Future avenues of investigation will be needed to answer a number of remaining questions. For instance, upon LysoPC removal, why don't all asexual parasites convert to gametocytes? This implies that the epigenetic silencing of the ap2-g locus is only removed in a subset of cells and that other factors are involved. Single-cell analyses of Plasmodium parasites are needed to examine the effect of LysoPC in individual cells, and recently, Poran et al. (2017) have demonstrated that such studies are feasible and very informative to dissect transcriptional changes associated in gametocyte-committed cells. Along these lines-although this work reveals that the depletion of LysoPC results in relatively equivalent increases in gametocyte production across strains when comparing Pf2004, HB3, and NF54 strains of P. falciparum-previous studies have demonstrated that gametocyte production is strain and clone dependent (Brancucci et al., 2015; Kafsack et al., 2014) . These differences in gametocyte levels indicate that differential responses to LysoPC may result from genetic variation between strains.
It is now clear that LysoPC is a critical metabolite that is sensed by the parasite and acts upstream of any previously described event of sexual differentiation. However, this study also highlights that there is still much to be learned to clarify our understanding of the mechanisms underlying sexual commitment and differentiation. Future studies are critical, since targeted therapies aimed at interfering with gametocyte formation are an important component of ongoing efforts to eliminate malaria globally by blocking its transmission. The balance between asexual parasite replication and sexual differentiation is explored in every 48-hr cycle of the human malaria parasite Plasmodium falciparum's developmental cycle. Brancucci et al. have identified lysophosphatidylcholine (LysoPC) as an important molecule whose presence (at low parasitemia) represses conversion to the sexual gametocyte form required for transmission to the mosquito host. LysoPC is a host-derived lipid that is metabolized by the parasite into critical membrane phospholipids. Decreased levels of LysoPC result in transcriptional activation of key enzymes required to replenish phospholipid stores via S-adenosylmethioine (SAM)-mediated reactions, including S-adenosylmethioine synthetase (SAMS) and phosphoethanolamine methyltransferase (PMT). This diversion of SAM activity suggests a potential interplay of metabolic adjustments that likely result in a decrease in H3K9me3 and a concomitant derepression of the gene encoding the critical AP2-G transcription factor (Kafsack et al., 2014) required to drive gametocyte commitment and differentiation.
Combination therapy programs are the hallmark of the successful treatment of all forms of human malignancies. In this issue of Cell, Palmer and Sorger present data suggesting that cell culture results indicative of synergistic anticancer drug interactions rarely translate clinically and that the results of combination therapies in mouse models or human clinical trials, even if successful, are best explained by the independent activities of the individually administered drugs.
Early in the development of cytotoxic cancer chemotherapy, basic principles guiding the use of combination therapies were established based primarily on the work of Frei and Freireich (Frei et al., 1965) , Sartorelli (Sartorelli, 1969) , and DeVita and colleagues (DeVita and Schein, 1973) . As elucidated, these principles suggest that (1) drugs used in combination should cause measurable tumor regressions when employed individually, (2) each ought to demonstrate a different mechanism of action to minimize the development of resistance, (3) the clinical toxicities of each compound should not overlap to permit their use in effective doses, and (4) intensive intermittent treatment is preferred over continuous, lowdose therapy to enhance cytoreduction (Kummar et al., 2010) . However, the molecular basis for the selectivity of the cytotoxic agents used for the first effective clinical trials of this approach, in their disease contexts, was not known. Over the past 15 years, the availability of anticancer agents with greater molecular specificity of action has engendered new rules for the development of combinations, which suggests that the prospective design of molecularly targeted combinations, inhibiting multiple pathway dependencies, might lead to complementary growth inhibition and enhanced therapeutic activity (Kwak et al., 2007) .
In this issue of Cell, Palmer and Sorger suggest that most commonly used combination chemotherapy regimens provide benefit via a spectrum coverage mechanism based on the independent actions of individual drugs rather than through their additive or synergistic effects (Palmer and Sorger, 2017) . The independent action model, illustrated in Figure 1 , assumes that the population outcome for patients receiving the combination of drug A + drug B equals the maximum outcome the patient population would have experienced had they received the same doses of either drug A or drug B as single agents. Hence, even when no patient benefits from the combination relative to what he or she would have experienced with an optimally selected single agent, the number of patients that benefit following combination
